FDA Endorses PBPK Modeling To Support Post-Approval Changes
The US FDA endorses the use of physiologically based pharmacokinetic (PBPK) models to support formulation and manufacturing changes.
You may also be interested in...
New EU guideline will describe how drug developers should go about using physiologically-based pharmacokinetic (PBPK) modeling tools to help predict drug interactions, establish dosing in pediatric or Phase I trials, and other regulatory functions.
FDA’s attempt to show it is staying abreast of changes in the way drug interaction studies are conducted have some in the industry saying the agency has gotten ahead of itself.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.